News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

(Image Credits: Pexels) The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated this month to recommend ribociclib (Kisqali) as a Category 1 preferred ...

Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...

Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a Category 1 preferred CDK4/6 inhibitor adjuvant therapy ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price ...

Ribociclib, in combination with the aromatase inhibitor letrozole, improves survival in post-menopausal women with hormone receptor-positive metastatic breast cancer. Breast cancer is a cancer ...

“One-third of people diagnosed with stage II breast cancer and more than half of those diagnosed with stage III will unfortunately experience a return of their cancer in the long term, often as ...